度普利尤单抗致银屑病相关不良反应文献分析  

Literature Analysis of Psoriasis-Related Adverse Reactions Induced by Dupilumab

作　　者：张文 崔建蓉[2] ZHANG Wen;CUI Jianrong(Sichuan Provincial Maternity and Child Health Care Hospital,The Affiliated Women's and Chilaren's Hospital of Chengdu Medical College,Chengdu,Sichuan,China 610031;Chengdu Seventh People's Hospital,Chengdu,Sichuan,China 610200)

机构地区：[1]四川省妇幼保健院·成都医学院附属妇女儿童医院,四川成都610031 [2]四川省成都市第七人民医院,四川成都610200

出　　处：《中国药业》2025年第4期124-128,共5页China Pharmaceuticals

基　　金：四川省成都市医学科研课题[2023573]。

摘　　要：目的为临床安全使用度普利尤单抗提供参考。方法收集中国知网、万方、维普及PubMed、Embase、Web of Science数据库2017年3月至2023年11月收载的度普利尤单抗致银屑病及银屑病样皮损相关文献,分析病例特征。结果共纳入33篇文献,其中中文1篇,英文32篇;涉及患者48例,其中41例为新发,4例为原有加重,3例不详。患者中,男27例,女21例;年龄以40~59岁最多(33.33%)。有银屑病个人史或家族史及两者兼有的均为2例,39例均无,3例不详;既往病史以过敏性鼻炎最多(11例,22.92%);用药原因以特应性皮炎为主(44例,91.67%);相关药品不良反应潜伏期10天至2.5年,主要发生在用药后6个月内(34例,70.83%);临床分型以斑块状银屑病为主(24例,50.00%);病灶位置主要分布在四肢(30例,62.50%)及躯干(15例,31.25%)。47例(97.92%)经停药或减量和/或对症处理后好转。结论临床需警惕度普利尤单抗银屑病相关不良反应,尤其对于有高危因素(男性,40~59岁,银屑病病史或家族史,过敏性鼻炎或哮喘)患者。用药期间应加强监测新发或加重皮炎,尽早识别诊断,对症治疗,保障用药安全。Objective To provide a reference for the safe use of dupilumab in clinical practice.Methods Literature psoriasis and psoriatic-like skin lesions induced by dupilumab from March 2017 to November 2023 in the PubMed,Embase and Web of Science was collected,and the case characteristics were analyzed.Results A total of 33 articles were included,including 1 in Chinese and 32 in English;48 patients were involved,of which 41 had newly-diagnosed diseases,4 had previously aggravated diseases,and 3 were unknown.Among the patients,there were 27 males and 21 females,mainly aged 40-59 years(33.33%).Two cases had a personal/family history of psoriasis or both,39 cases had no the above medical history,and three cases of diseases were unknown;the most common medical history was allergic rhinitis(11 cases,22.92%);the main reason for medication was atopic dermatitis(44 cases,91.67%);the latency of adverse drug reactions(ADRs)was 10 d to 2.5 years,mainly occurring within six months after medication(34 cases,70.83%);the clinical classification was mainly plaque psoriasis(24 cases,50.00%);the lesion location were mainly distributed in the four limbs(30 cases,62.50%)and trunk(15 cases,31.25%).A total of 47 cases(97.92%)improved after withdrawal or dosage reduction and/or symptomatic treatment.Conclusion We should be paid to the psoriasis-related ADRs induced by dupilumab,especially for the patients with high-risk factors(male,40-59 years,history of psoriasis or family history,complicated with allergic rhinitis or asthma).During medication,it is necessary to strengthen monitoring of newly-developed or aggravated dermatitis,identify and diagnose it as early as possible,and give symptomatic treatment to ensure medication safety.

关 键 词：度普利尤单抗 银屑病 药品不良反应 文献分析 

分 类 号：R969.3[医药卫生—药理学]